The 6 Most Common FDA Software Validation Failures and How to Prevent Them

Overview:

One of the most concerning findings during an FDA inspection is discovering that an electronic record can be modified without a reliable history of what changed, who made the change, or why. In a March 2026 Warning Letter, FDA identified electronic batch-record modifications made through a software vendor without corresponding audit trail entries. Another Warning Letter issued in May highlighted unvalidated laboratory software, missing audit trail controls, and inadequate protection of electronic test data. These findings illustrate how weaknesses in computerized system controls can compromise data integrity, undermine confidence in validation practices, and expose manufacturers to significant regulatory consequences.

The regulatory environment has also evolved. In February 2026, FDA issued revised final guidance on Computer Software Assurance for medical device production and quality management system software, reinforcing a risk-based approach to establishing confidence in computerized systems. The implementation of the Quality Management System Regulation (QMSR) introduced a revised inspection framework for medical device manufacturers, while pharmaceutical companies continue to face scrutiny over computerized system controls, electronic records, and data integrity. These developments bring renewed attention to the decisions organizations make when validating software and maintaining evidence of compliance.

For validation professionals, the challenges often begin with determining what needs to be validated and how much testing is appropriate. Organizations must establish which systems and electronic records fall within the scope of 21 CFR Part 11 or EU Annex 11, verify security controls, audit trails, and electronic signatures, and evaluate the responsibilities associated with locally installed, SaaS, and cloud-hosted applications. Unclear requirements, inadequate project staffing, poorly defined vendor responsibilities, and inconsistent testing practices can result in unnecessary documentation, implementation delays, and compliance gaps that remain undiscovered until an audit or inspection.

This webinar will examine the six most common problems encountered in FDA software validation and verification and explain practical strategies for avoiding them. David Nettleton will address critical considerations for regulated software systems, including electronic record requirements, security and audit trail functionality, different software hosting environments, and effective validation project staffing. The discussion will also explore why sound validation practices make business sense by reducing avoidable project costs, rework, and the need for corrective action.

For professionals responsible for validating, implementing, maintaining, or overseeing computerized systems, understanding these recurring problems can help improve project planning, strengthen validation documentation, and support more consistent compliance decisions. The session will provide practical guidance for identifying weaknesses before they become costly findings, maintaining defensible validation evidence, and reducing exposure to FDA Form 483 observations and Warning Letters.

Areas covered in the session:

• Which data and systems are subject to 21 CFR Part 11 and Annex 11
• Why compliance makes good business sense.
• Details of FDA regulations/system features as applied to software: security, audit trails, electronic signatures.
• Requirements for local, SaaS, and cloud hosting
• The 6 Most Common Problems in FDA Software Validation & Verification.
• Strategies on how to avoid the most common problems.
• Advice on successful validation project staffing.
• Avoid 483 and Warning Letters.

Why Should You Attend?

Software validation problems can remain hidden for months or even years, only to surface during an FDA inspection, system upgrade, or investigation involving electronic records. By that point, correcting the deficiencies may require extensive remediation, additional testing, revised documentation, and significant resources. Understanding where validation projects commonly fail can help organizations identify weaknesses earlier, make better decisions about system controls, and maintain reliable evidence of compliance.

This webinar will help attendees evaluate their existing validation practices and recognize gaps involving 21 CFR Part 11, EU Annex 11, security controls, audit trails, electronic signatures, and software hosting arrangements. Participants will gain a clearer understanding of how to approach validation planning, determine appropriate project resources, avoid unnecessary testing and documentation burdens, and address recurring problems that can undermine inspection readiness. These considerations are particularly valuable for organizations implementing new systems, transitioning to SaaS or cloud-based applications, or maintaining established computerized systems.

Drawing on his extensive experience in FDA-regulated computerized systems, David Nettleton will examine six recurring validation and verification problems and share practical strategies for preventing them. Attendees will leave with a better understanding of where to focus their validation efforts, how to strengthen the reliability of their supporting documentation, and what steps can help reduce the likelihood of FDA Form 483 observations, Warning Letters, and costly corrective actions.

Who Will Benefit?

This webinar is intended for professionals responsible for software validation, computerized system compliance, data integrity, and the implementation and maintenance of FDA-regulated systems. It is particularly relevant to individuals working in pharmaceutical, biotechnology, medical device, and other FDA-regulated organizations. Those include:

• Computer System Validation (CSV) Managers
• Computer System Validation (CSV) Specialists
• Computer Software Assurance (CSA) Professionals
• Software Validation Engineers
• Software Verification and Validation (V&V) Engineers
• Validation Managers
• Validation Engineers
• Quality Assurance (QA) Managers
• Quality Assurance (QA) Specialists
• Quality Systems Managers
• Quality Compliance Managers
• Regulatory Compliance Managers
• Data Integrity Managers and Specialists
• 21 CFR Part 11 Compliance Specialists
• GxP Compliance Managers and Specialists
• IT Quality Assurance Managers
• IT Compliance Managers
• GxP IT Managers
• Computerized Systems Managers
• Laboratory Information Management System (LIMS) Administrators
• Manufacturing Execution System (MES) Managers
• Electronic Quality Management System (eQMS) Administrators
• Laboratory and Manufacturing Systems Validation Specialists
• Software Implementation and Validation Project Managers
• Quality and Regulatory Auditors